ERBB3 and non-small cell lung carcinoma: The development of U3–1287/AMG-888 (originally developed by Amgen Inc., Thousand Oaks, CA; later acquired by Daiichi Sankyo Co. Ltd., Tokyo, Japan and re-named as patritumab) is the first fully humanized, anti-HER3 monoclonal Ab that is currently being examined in several clinical trials in patients with advanced solid tumors [18], including a phase III trial in patients with NSCLC [85].